Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717195 · ClinicalTrials.gov registry record · Phase 3
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,098
- Enrollment target
NCT02717195 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 1,098 participants.
The verdict
NCT02717195, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,098 participants
- Enrollment target
Study Summary
To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Lu AF35700
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,098 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-10-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02717195
The ClinicalTrials.gov registry entry for NCT02717195 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,098 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Risperidone is the first listed.
NCT02717195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02717195 about?
NCT02717195 is a clinical study titled "Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia". To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)
What is the current status of trial NCT02717195?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,098 participants. The study started on 2016-04. Estimated completion is 2018-10-08.
What interventions are being tested in trial NCT02717195?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Lu AF35700 (DRUG).
Who is sponsoring clinical trial NCT02717195?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.